AI-assisted international press reviewPress review

Sanofi Opens New Insulin Manufacturing Plant in Frankfurt, Germany

Sanofi has begun construction on an insulin manufacturing facility in Frankfurt, aimed at modernizing insulin production and ensuring a reliable supply for millions of diabetics worldwide. Spanning 36,000 square meters, this facility will incorporate advanced technologies and artificial intelligence, and is expected to be operational by 2032, addressing the growing global demand for insulin.

Source: Sanofi, published under the title "Press Release: Sanofi breaks ground on new state-of-the-art ..." - 19 October 2026

Merck Unveils 25 Oncology Abstracts at ESMO 2026 Conference

At the ESMO 2026 congress, Merck will highlight significant advancements in the treatment of various cancers, including updates on the efficacy and safety of new therapies such as pimicotinib and precemtabart tocentecan. These presentations aim to address unmet medical needs and enhance the quality of life for patients with rare and complex cancers. The data presented reflects Merck's commitment to translating scientific innovation into meaningful clinical outcomes for patients.

Source: Merck, published under the title "Merck to Present 25 Abstracts at ESMO 2026 Highlighting Adva..." - 19 October 2026

AstraZeneca Unveils Key Overall Survival Data at ESMO 2026

At the ESMO 2026 congress, AstraZeneca will present promising results from four Phase III clinical trials, highlighting innovative treatments for gastric, lung, and bladder cancers. Data from CLARITY-Gastric01, SAFFRON, VOLGA, and DeLLphi-305 demonstrate the potential of drug combinations to improve clinical outcomes and redefine standards of care in oncology. These advancements underscore AstraZeneca's commitment to transforming cancer care through precision medicine approaches.

Source: Astrazeneca, published under the title "AstraZeneca to present overall survival data from four pivot..." - 19 October 2026

Merck Strengthens Portfolio by Acquiring Silence Therapeutics for $1.1 Billion

Merck's acquisition of Silence Therapeutics for $1.1 billion aims to integrate an innovative siRNA therapy for polycythemia vera, thereby enhancing Merck's position in the rare disease sector and supporting its ambition to become a global leader in specialized health innovation.

Source: Merck, published under the title "Merck to Acquire Silence Therapeutics, Strengthening Rare Di..." - 19 October 2026

TREMFYA Shows Sustained Efficacy in Treating Perianal Fistulas at 48 Weeks

Phase 3 study results indicate that TREMFYA (guselkumab) maintains or improves remission of perianal fistulas in patients with Crohn's disease, with a significant increase in remission rates at 48 weeks. These findings highlight the importance of this treatment in a challenging condition, offering new perspectives for patients.

Source: J&j - 19 October 2026

GSK Reveals Promising Data on Ris-Rez for Lung Cancer Treatment

GSK announced an overall response rate of 61% for Ris-Rez in a Phase Ib trial, reinforcing previous positive results and supporting the accelerated development of the treatment as part of an ongoing Phase III trial.

Source: Gsk, published under the title "GSK presents first global data for Ris-Rez in extensive-stag..." - 19 October 2026

GSK Highlights Advances Against Cancer at ESMO 2026 Conference

At the ESMO 2026 conference, GSK showcased promising data on its oncology treatments, including positive results for Ris-Rez in lung cancer and significant advancements in the treatment of ovarian and rectal cancers, emphasizing the potential impact of these innovative therapies on patient care.

Source: Gsk, published under the title "GSK showcases pipeline momentum across lung, gynaecological ..." - 17 October 2026

Sanofi Partners with Tour de France to Promote Health Awareness

Starting in 2027, Sanofi will be the first sponsor of the Tour de France's white jersey, aiming to raise public awareness on health issues and scientific education. This partnership is part of a broader strategy by Sanofi to leverage sports as a communication vehicle for health, in collaboration with healthcare professionals and patient organizations.

Source: Sanofi, published under the title "Press release: Sanofi to become major partner of the Tour de..." - 16 October 2026

EMA Recommends TALVEY® Combined Therapy for Multiple Myeloma Treatment

Johnson & Johnson announced that the EMA's CHMP recommends the approval of TALVEY® in combination with daratumumab for the treatment of recurrent or refractory multiple myeloma. This innovative combination specifically targets myeloma cells while preserving healthy immune cells, providing a promising new therapeutic option for patients who have already received treatment. Results from the MonumenTAL-3 study show significant improvements in progression-free survival and overall survival, highlighting the importance of this approach in the treatment journey of patients.

Source: J&j - 16 October 2026

Vividion Therapeutics Launches Phase II Trial for VVD-214 in Colorectal Cancer

Vividion Therapeutics has announced the initiation of a Phase II clinical trial for its inhibitor VVD-214, in combination with pembrolizumab, aimed at treating advanced colorectal cancer with microsatellite instability. This trial expands the clinical development of VVD-214, which has shown promising results in preliminary studies. Colorectal cancer, affecting a significant portion of the population, requires new effective and better-tolerated therapeutic options.

Source: Bayer, published under the title "Vividion Therapeutics Expands Clinical Development of WRN In..." - 15 October 2026

EU and UK Risk Losing Agricultural Strategic Autonomy

A study reveals that limited access to innovation hinders the competitiveness of European farmers against global competitors. Rising input costs and the impacts of climate change exacerbate the situation, while consumers support a faster adoption of technologies to enhance food security and the resilience of farms.

Source: Bayer, published under the title "EU and UK Risk Falling Further Behind Global Agricultural Co..." - 15 October 2026

Bayer Foundation Honors Researchers for Contributions in Agritech and Health

In 2026, the Bayer Foundation awarded its Science Awards to five scientists, including Sarah O’Connor, for their innovative research in biology, chemistry, and plant sciences. These awards highlight work with potential impacts on health, agriculture, and sustainable innovation, particularly in drug production and crop disease resistance.

Source: Bayer, published under the title "Bayer Foundation honors five outstanding scientists with the..." - 14 October 2026

Johnson & Johnson Reports Strong Growth and Optimistic Outlook for 2026

In the third quarter of 2026, Johnson & Johnson reported a 6% increase in sales, driven by advancements in oncology and strategic investments in the MedTech sector. The company anticipates exceeding $100 billion in annual revenue for the first time, with ambitions for double-digit growth by 2030. The results reflect a solid performance and renewed confidence in innovation and the development of new products.

Source: J&j - 14 October 2026

Sustainable Efficacy of TREMFYA in Crohn's Disease: Promising Results

New data from Johnson & Johnson reveal that TREMFYA (guselkumab) maintains significant clinical and endoscopic remission rates in adults with active Crohn's disease, providing encouraging prospects for the long-term management of this chronic condition.

Source: J&j - 14 October 2026

TREMFYA® Shows Confirmed Efficacy for Treating Perianal Fistulas in Crohn's Disease

Johnson & Johnson has presented new Phase 3 data on TREMFYA® (guselkumab), demonstrating promising results for patients with perianal fistulas related to Crohn's disease. Subgroup analyses revealed consistent efficacy, underscoring the importance of this treatment in a challenging patient population. These results were shared at the American College of Gastroenterology 2026, highlighting the company's commitment to innovation in the field of inflammatory bowel diseases.

Source: J&j - 14 October 2026

Johnson & Johnson Reports 5.9% Sales Growth in Q3 2026

In the third quarter of 2026, Johnson & Johnson recorded a 5.9% sales growth, reaching $25.4 billion, with notable advancements in its MedTech innovations and promising results in oncology. The CEO expressed confidence in the company's ability to achieve double-digit growth by the end of the decade, despite a significant decline in net profits. The innovative medicine and medical technology segments continue to grow, strengthening the company's market position.

Source: J&j - 13 October 2026

Community Health: Screening Initiatives in Hair Salons

The innovative screening initiative in hair salons aims to improve healthcare access for underserved communities. By integrating health services into everyday living spaces, this approach could transform the delivery of preventive care while strengthening social ties and health awareness within neighborhoods. However, this initiative does not fall within the scope of plant technologies or agritech, raising questions about its relevance in the current context.

Source: Novartis, published under the title "Community health takes a village: Screening in the barber’s ..." - 13 October 2026

Johnson & Johnson Declares $1.34 Dividend for Q4 2026

The board of directors of Johnson & Johnson has declared a dividend of $1.34 per share for the fourth quarter of 2026, payable on December 8 to shareholders of record as of November 24. The company continues to focus on health innovation, aiming to transform medical treatments and improve quality of life.

Source: J&j - 13 October 2026

Efzimfotase Alfa: Significant Improvement in Walking Test for Hypophosphatasia Patients

Results from the Phase III HICKORY trial indicate that efzimfotase alfa, while not achieving statistical significance, led to a numerical improvement in the six-minute walk test and other functional measures among adolescents and adults with hypophosphatasia. These promising results could pave the way for a new therapy for this rare disease, which has recently been submitted for priority review in the United States.

Source: Astrazeneca, published under the title "Efzimfotase alfa showed numerical improvement in Six-Minute ..." - 12 October 2026

Promising Results for ICOTYDE in Psoriasis Treatment Revealed by Johnson & Johnson

Johnson & Johnson has unveiled results from the ICONIC-LEADa study, showing that ICOTYDE, a targeted oral peptide, offers high and sustained response rates in patients with moderate to severe psoriasis. With nearly 72% of patients achieving clear or almost clear skin after two years, this innovation could transform treatment options for this chronic disease. The data also confirm a favorable safety profile, with no new safety signals identified, reinforcing ICOTYDE's position as a first-line systemic therapy.

Source: J&j - 9 October 2026